Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FUROSEMIDE vs DEMADEX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Furosemide is a loop diuretic that inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium ions, leading to increased urine output.
Inhibits the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Edema associated with heart failure, cirrhosis, renal disease,Hypertension,Hypercalcemia (off-label)
Edema associated with heart failure, hepatic cirrhosis, and renal disease,Hypertension (off-label)
Adults: 20-80 mg orally once or twice daily; IV/IM: 20-40 mg once or twice daily, may increase by 20-40 mg every 6-8 hours. Max dose: 600 mg/day.
Oral: 5-10 mg once daily; may increase to 20 mg once daily if needed. IV: 5-10 mg once daily; may increase to 20 mg once daily if needed. Maximum dose: 40 mg/day.
0.5-2 hours (terminal); prolonged in renal impairment (up to 9-24 hours) and hepatic cirrhosis (up to 2-4 hours).
The terminal elimination half-life is approximately 4 hours (range 2-8 hours) in patients with normal renal function. In renal impairment (creatinine clearance <30 m L/min), half-life is prolonged to 10-12 hours due to reduced renal clearance. In hepatic cirrhosis, half-life may be extended to 8-9 hours due to decreased metabolism.
Furosemide is primarily metabolized via glucuronidation (by UGT1A1, UGT1A9) and to a lesser extent by CYP450 enzymes (minor).
Primarily hepatic via CYP450 enzymes, with minimal renal clearance.
Renal (50-80% unchanged; remainder as glucuronide metabolite); fecal (<2%).
Approximately 50% of the absorbed dose is excreted unchanged in the urine via glomerular filtration and active tubular secretion. The remainder undergoes hepatic metabolism to glucuronide conjugates and minor oxidative metabolites, with biliary excretion of metabolites (about 30-40% of the dose) eliminated in feces. Renal clearance is the primary route for the parent drug.
91-99% (primarily to albumin).
Torsemide (DEMADEX) is extensively bound to plasma proteins, primarily albumin, with a protein binding of >99%.
0.1-0.2 L/kg; increased in neonates (0.2-0.4 L/kg) and disease states (e.g., heart failure, cirrhosis).
The apparent volume of distribution (Vd) is approximately 0.16 L/kg (range 0.12–0.20 L/kg), indicating distribution primarily within extracellular fluid. Vd is increased in conditions with expanded extracellular volume (e.g., heart failure, cirrhosis, nephrotic syndrome).
Oral: 50-60% (variable, 10-100% range due to food and formulation); IM: 100% (relative to IV).
Oral bioavailability is approximately 80–90%, with minimal first-pass metabolism. Absorption is rapid and not significantly affected by food.
GFR 10-50 m L/min: dose unchanged; GFR <10 m L/min: avoid use or use with caution; anuric patients: contraindicated.
GFR <20 m L/min/1.73 m²: Use with caution; may require dose reduction or discontinuation due to accumulation. GFR 20-50: No adjustment needed. GFR >50: No adjustment.
Child-Pugh A-B: no adjustment; Child-Pugh C: reduce dose by 50% and monitor response; increased risk of hypokalemia and volume depletion.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50% or extend interval. Child-Pugh C: Avoid use or reduce dose by 75%.
Oral: 1-2 mg/kg/dose every 6-12 hours; IV/IM: 1 mg/kg/dose every 6-12 hours; max dose: 6 mg/kg/dose. Not recommended in neonates unless critical.
Neonates and infants: 0.1-0.2 mg/kg/dose IV/IM once daily. Children: Oral: 0.5-1 mg/kg once daily; IV/IM: 0.1-0.2 mg/kg/dose once daily. Maximum: 5 mg/day.
Start at lowest effective dose (e.g., 20 mg orally once daily); monitor electrolytes, renal function, and volume status closely; avoid excessive diuresis.
Start at lower end of dose range (2.5-5 mg orally once daily); titrate slowly due to increased sensitivity and renal impairment risk.
Furosemide is a potent diuretic; excessive diuresis may lead to profound electrolyte depletion, volume depletion, and circulatory collapse.
None.
Monitor for electrolyte imbalances (hypokalemia, hyponatremia, hypomagnesemia),Risk of ototoxicity, especially with rapid infusion or concurrent use of other ototoxic drugs,Monitor renal function and blood pressure; caution in patients with severe hepatic cirrhosis or renal impairment,May cause photosensitivity, blood dyscrasias, and hypersensitivity reactions
Hypotension and volume depletion,Electrolyte imbalances (hypokalemia, hyponatremia, hypochloremia),Ototoxicity (especially with rapid IV administration or high doses),Hyperuricemia,Sulfonamide allergy cross-reactivity
Anuria,Severe electrolyte depletion,Hypersensitivity to furosemide or sulfonamides,Hepatic coma or precoma (relative)
Anuria,Severe electrolyte depletion,Hypersensitivity to sulfonamides or bumetanide (Demadex is a sulfonamide derivative)
Avoid excessive salt intake to prevent fluid retention and counteract diuretic effect. Limit alcohol as it can increase diuretic effect and cause dehydration. May increase potassium loss; consider potassium-rich foods (bananas, oranges, spinach) unless contraindicated (e.g., with ACE inhibitors). No specific restrictions with grapefruit juice.
Avoid excessive licorice intake (glycyrrhizin) as it can exacerbate hypokalemia. Limit sodium-rich foods (processed foods, canned soups) to enhance diuretic effect and control edema. Increase potassium-rich foods (bananas, oranges, potatoes) unless on a potassium-sparing medication. Avoid grapefruit juice as it may affect metabolism.
Furosemide is pregnancy category C. First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses, but fetal toxicity (hydronephrosis) at high doses. Second/third trimesters: Risk of electrolyte imbalance in mother and fetus, potential for decreased placental perfusion due to maternal hypovolemia. Use only if benefit outweighs risk, especially in oligohydramnios or preeclampsia.
DEMADEX (torsemide) is a loop diuretic. Human data are limited. In animal studies, high doses caused fetal resorptions and maternal toxicity. First trimester: insufficient human data; avoid unless benefit outweighs risk. Second/third trimester: risk of fetal oligohydramnios, renal impairment, and hypovolemia; use only if clearly needed.
Furosemide is excreted into breast milk in low amounts (M/P ratio approximately 2.6). Theoretical risk of electrolyte imbalance in infant. Consider using lowest effective dose and monitor infant for signs of dehydration or electrolyte disturbances.
Torsemide is excreted in breast milk in small amounts; M/P ratio not reported. Due to potential for diuresis, electrolyte imbalance, and allergic reactions in the infant, caution is recommended. Alternative diuretics with more safety data are preferred.
Pregnancy increases renal clearance and volume of distribution, potentially reducing plasma furosemide levels, but dosing adjustments are not routinely recommended due to risk of hypovolemia. Use lowest effective dose and titrate based on response, with close monitoring.
Dosing may need adjustment due to increased plasma volume and GFR in pregnancy. Start at lowest effective dose. Monitor diuretic response and electrolyte balance; dose titration may be required. Postpartum, drug elimination may return to prepregnancy kinetics.
Monitor urine output and electrolytes, especially potassium. Avoid use in anuria, severe electrolyte depletion, and hepatic coma. Can cause ototoxicity, especially with rapid IV administration or concurrent use of other ototoxic drugs. Sulfonamide allergy may cross-react; use caution. Loop diuretics like furosemide are effective in renal impairment, unlike thiazides.
DEMADEX (torsemide) is a loop diuretic with high bioavailability (80-100%) and a longer half-life (3-4 hours) than furosemide, allowing once-daily dosing. It is primarily metabolized by CYP2C9, so caution is needed with CYP2C9 inhibitors like amiodarone. Monitor for ototoxicity at high doses or rapid infusion. Hypokalemia risk persists; consider potassium supplementation or aldosterone antagonist. Use cautiously in sulfonamide allergy due to potential cross-sensitivity.
Take exactly as prescribed, preferably in the morning to avoid nighttime urination.,Weigh yourself daily and report rapid weight gain or loss.,Avoid alcohol and NSAIDs as they may reduce diuretic effect or increase kidney damage.,Report hearing loss, ringing in ears, dizziness, or muscle cramps immediately.,Do not stop suddenly without consulting your doctor; may cause rebound edema.,Limit high-potassium foods if also taking ACE inhibitors or potassium-sparing diuretics.,Stay hydrated but avoid excessive fluid intake.
Take DEMADEX exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,Weigh yourself daily and report sudden weight gain or loss of more than 2-3 pounds in a day.,Avoid alcohol and beverages containing caffeine as they may increase dehydration.,Do not take DEMADEX with licorice (which can worsen hypokalemia) or with high-sodium antacids.,Report signs of hearing loss, ringing in the ears, dizziness, or muscle cramps immediately.,Stand up slowly to prevent dizziness from low blood pressure.,Monitor for signs of dehydration: dry mouth, thirst, infrequent urination.
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Zaltoprofen, a nonsteroidal anti-inflammatory drug (NSAID), reduces the antihypertensive and diuretic efficacy of furosemide by inhibiting renal prostaglandin synthesis. This blockade diminishes renal blood flow and natriuretic response, potentially leading to fluid retention and diminished blood pressure control. The interaction may precipitate or exacerbate heart failure and edema in susceptible patients."
"Isoflurane, a halogenated inhalational anesthetic, can cause dose-dependent myocardial depression and systemic vasodilation, leading to decreased blood pressure and renal perfusion. Furosemide, a loop diuretic, further reduces intravascular volume and renal blood flow via inhibition of the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle. Co-administration may result in additive hypotension, acute kidney injury, and electrolyte imbalances (e.g., hypokalemia, hypomagnesemia), particularly in patients with pre-existing renal impairment or hemodynamic instability."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FUROSEMIDE vs DEMADEX, answered by our medical review team.
FUROSEMIDE is a Loop Diuretic that works by Furosemide is a loop diuretic that inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium ions, leading to increased urine output.. DEMADEX is a Loop Diuretic that works by Inhibits the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FUROSEMIDE and DEMADEX depend on the specific clinical indication. These are both Loop Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FUROSEMIDE is: Adults: 20-80 mg orally once or twice daily; IV/IM: 20-40 mg once or twice daily, may increase by 20-40 mg every 6-8 hours. Max dose: 600 mg/day.. The standard adult dose of DEMADEX is: Oral: 5-10 mg once daily; may increase to 20 mg once daily if needed. IV: 5-10 mg once daily; may increase to 20 mg once daily if needed. Maximum dose: 40 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FUROSEMIDE and DEMADEX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FUROSEMIDE is classified as Category A/B. Furosemide is pregnancy category C. First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses, but fetal toxicity (hydronephrosis) at . DEMADEX is classified as Category C. DEMADEX (torsemide) is a loop diuretic. Human data are limited. In animal studies, high doses caused fetal resorptions and maternal toxicity. First trimester: insufficient human da. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.